ClinicalTrials.gg
CompletedNCT02832063Updated Sep 16, 2022Results posted

Clinical Trial in Subjects With Mild to Moderate Acne Vulgaris

A Phase 2/3 interventional study of B244 and Placebo in Acne Vulgaris, sponsored by AOBiome LLC. Completed at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2022-09-16.

Sponsored by AOBiome LLC · Phase 2/3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2/3
Study type
Interventional
Enrollment
372
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 373 studies in Acne Vulgaris with a site in United States — 20 open to participants now, 29 under way, 2 of them phase 3. Acne Vulgaris · United States.

Enrollment
93rd of 353
372 · median 78
Started
2016
with 33 others
Phase 2/3
6 of 373
1 open now
Registered
208th of 373
by date

Among the 373 studies in Acne Vulgaris with a site in United States, this one is the 93rd largest by enrollment of the 353 interventional ones that give a count, is one of 34 that started in 2016, is one of 6 in phase 2/3, and was the 208th registered.

Acne Vulgaris

791 studies on the registry are indexed under Acne Vulgaris; 94 are open to participants now.

Browse Acne Vulgaris studies →

Open to participants now

20 of the 373 studies in Acne Vulgaris with a site in United States are open now. Recruiting first, the newest first:

15 more — sign in →

All 20 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 47 Acne Vulgaris studies recruiting now, 17 (36%) set no upper age limit and 29 (62%) stop at 75 or younger; 21 take children under 18; 17 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 373 studies in Acne Vulgaris with a site in United States, or all of them as a file.
02

Study summary

The purpose of this study is to demonstrate the safety, tolerability and efficacy of B244 administered over 12 weeks to participants with mild to moderate acne vulgaris relative to placebo.

Read the detailed description

This is a Phase IIb/III, randomized, double blinded, decentralized clinical trial evaluating the safety, tolerability, and efficacy of B244 compared to placebo in the treatment of acne vulgaris

1.1. Primary Objectives

  1. To evaluate the safety and tolerability of B244 in participants with acne vulgaris
  2. To assess the efficacy of B244 in participants with mild to moderate acne vulgaris from baseline to week 12 (end of treatment) by:

    i) Reduction in inflammatory and non-inflammatory lesion count ii) IGA success

  3. Improvement in patient reported quality of life score using the Skindex-16 questionnaire in participants with acne vulgaris from baseline to week 12

1.2. Secondary Objectives 1. To evaluate the efficacy of B244 in participants with mild to moderate acne vulgaris from baseline to weeks 2, 4, 8, and 16: i) Reduction in inflammatory and non-inflammatory lesion count ii) IGA success iii) Improvement in patient reported quality of life score using the Skindex-16 questionnaire

1.3. Exploratory Objective

  1. To evaluate facial skin microbiota in participants with acne vulgaris at baseline, week 4, week 8, week 12, and week 16 in B244-treated participants compared to placebo from: i) Skin swabs will be taken from forehead, nose, both cheeks and chin All participants (placebo and B244) will undergo skin swabs and testing.
03

Conditions studied

  • Acne Vulgaris

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Participants eligible for enrollment in the study must meet all the following criteria:

  1. Male and females age 18 or older
  2. Clinical diagnosis of mild to moderate facial acne vulgaris defined as:

    1. ≥5 inflammatory lesions, and;
    2. ≥10 non-inflammatory lesions, and;
    3. IGA 2-3
  3. Willing to refrain from using any treatments, other than the product, for acne present on the face. This includes the use of antibiotics for the treatment of acne. Topical acne treatments that do not have significant or measurable systemic absorption (e.g., benzoyl peroxide, salicylic acid) are allowed for treatment of non-facial acne.
  4. Willing and able to provide and to comply with the study protocol.

Exclusion criteria

Exclusion Criteria:

  1. Pregnant and/or lactating females
  2. Continuous or planned use of tanning booths or excessive sun exposure, in the opinion of the Investigator.
  3. Active cystic acne or acne conglobata, acne fulminans, and secondary acne
  4. Two or more active nodular lesions
  5. Treatment with over-the-counter topical medications for the treatment of acne vulgaris including benzoyl peroxide, topical anti-inflammatory medications, , α-hydroxy/glycolic acid, or topical probiotics including commercially available product AO+Mist on the face within 7 days prior to baseline.
  6. Treatment with systemic corticosteroids within 28 days prior to baseline.
  7. Treatment with systemic antibiotics or systemic anti-acne drugs within 7 days prior to baseline.
  8. Prescription topical retinoid use on the face within 7 days of baseline (e.g., tretinoin, tazarotene, adapalene).
  9. Commencement of new hormonal therapy or dose change to hormonal therapy within 90 days prior to baseline. Dose and frequency of use of any hormonal therapy started more than 90 days prior to baseline must remain unchanged throughout the study. Hormonal therapies include, but are not limited to, estrogenic and progestational agents such as pills.
  10. Use of androgen receptor blockers (such as spironolactone or flutamide) in the 7 days prior to randomization.
  11. Oral retinoid use (e.g., isotretinoin) within 180 days prior to baseline or vitamin A supplements greater than 10,000 units/day within 180 days of baseline.
  12. Cosmetic facial procedures (chemical or laser peel, microdermabrasion, etc.) within the 28 days of the first dose or during the study.
  13. History of sensitivity to any of the study medications, or components thereof or a history of drug or other allergy that, in the opinion of the Investigator or Medical Monitor, contraindicates their participation.
  14. Any condition that the study Investigator feels would indicate that participation would not be in the best interest of the participant.
  15. The participant has been previously randomized in this study.
  16. The participant has received an product within 30 days or 5 half-lives, whichever is longer prior to randomization.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 2 / Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
372 participants (actual)

Study arms

  • Active comparator
    B244 arm

    B244 dose administered in a 1:1 (active vs placebo) ratio

    Biological: B244

  • Placebo comparator
    Placebo arm

    Placebo dose administered in a 1:1 (active vs placebo) ratio

    Biological: Placebo

Interventions

  • BiologicalB244

    4 pumps of spray to saturate the entire face applied BID. Applications should occur in the morning and at night for 12 weeks.

  • BiologicalPlacebo

    4 pumps of spray to saturate the entire face applied BID. Applications should occur in the morning and at night for 12 weeks.

06

What researchers measure

Primary outcomes

  1. Number of Participants With Treatment RelatedAdverse Events

    Safety and tolerability endpoints will consist of all treatment related adverse events reporting during the study duration.

    Time frame: 16 weeks

  2. Change in Inflammatory and Non-inflammatory Lesion Count

    Lesion counting was performed using the digital photos taken by participants and stored inside the study mobile platform by trained personnel only. Every effort was made to have the counting and clinical evaluation done by the same evaluator for a given participant. Lesions under the jaw line or behind the hairline (including eyebrows) were not included in the counts. Papules, pustules, cysts and nodules were classified as inflammatory acne lesions, and open and closed comedones were classified as non-inflammatory lesions.

    Time frame: 12 weeks

  3. Number of Participants Demonstrating Efficacy Measured by Investigator Global Assessment Success

    IGA (Investigator's Global Assessment) was used to assess the overall diseases severity on a scale of 0 to 4 (0=clear, 1=almost clear, 2=mild disease, 3=moderate disease, and 4=severe disease). IGA success was defined as a post-baseline score of 0 or 1 (yes=success, no=no success).

    Time frame: 12 weeks

Secondary outcomes

  1. Change in Inflammatory and Non-inflammatory Lesion Count by Week

    Lesion counting was performed using the digital photos taken by participants and stored inside the study mobile platform by trained personnel only. Every effort was made to have the counting and clinical evaluation done by the same evaluator for a given participant. Lesions under the jaw line or behind the hairline (including eyebrows) were not included in the counts. Papules, pustules, cysts and nodules were classified as inflammatory acne lesions, and open and closed comedones were classified as non-inflammatory lesions.

    Time frame: Baseline to weeks 2, 4, 8, 12 and 16

  2. Number of Participants Demonstrating Efficacy Measured Investigator Global Assessment Score by Week

    IGA (Investigator's Global Assessment) was used to assess the overall diseases severity on a scale of 0 to 4 (0=clear, 1=almost clear, 2=mild disease, 3=moderate disease, and 4=severe disease). IGA success was defined as a post-baseline score of 0 or 1 (yes=success, no=no success).

    Time frame: Baseline to weeks 2, 4, 8, 12 and 16

  3. Change in Patient Reported Quality of Life Score Using the Skindex-16 Questionnaire

    The Skindex 16 questionnaire was assigned to subjects to examine the relationship between the subject's skin health and quality of life. Subjects scored 16 questions from 0 to 6 (0=never bothered, 6=always bothered). Total scores could range between 0 to 96, where a higher score is associated with a worse quality of life.

    Time frame: Baseline to weeks 2, 4, 8, 12 and 16

Other outcomes

  1. To Evaluate Facial Skin Microbiota

    Evaluate if B244 administration on skin twice daily will affect the microbial content on collected skin swab samples.

    Time frame: baseline, week 4, week 8, week 12, and week 16

07

Results

Posted Sep 16, 2022

Participant flow

Participant flow — Overall Study
MilestoneB244 ArmPlacebo Arm
Started186186
Completed152148
Not completed3438
Withdrew: Adverse event21
Withdrew: Physician decision57
Withdrew: Lost to follow-up158
Withdrew: Withdrawal by subject1021
Withdrew: Other21

Outcome measures

PrimaryNumber of Participants With Treatment RelatedAdverse Events

Safety and tolerability endpoints will consist of all treatment related adverse events reporting during the study duration.

Time frame:
16 weeks
Reported as:
Count of participants · Participants
Number of Participants With Treatment RelatedAdverse Events
ParticipantsB244 ArmPlacebo Arm
At Least 1 Treatment Related TEAE109
At Least 1 Treatment Related SAE00
PrimaryChange in Inflammatory and Non-inflammatory Lesion Count

Lesion counting was performed using the digital photos taken by participants and stored inside the study mobile platform by trained personnel only. Every effort was made to have the counting and clinical evaluation done by the same evaluator for a given participant. Lesions under the jaw line or behind the hairline (including eyebrows) were not included in the counts. Papules, pustules, cysts and nodules were classified as inflammatory acne lesions, and open and closed comedones were classified as non-inflammatory lesions.

Time frame:
12 weeks
Reported as:
Mean · lesions
Change in Inflammatory and Non-inflammatory Lesion Count
lesionsB244 ArmPlacebo Arm
Change in Inflammatory Lesion Count from Baseline to Week 12-4.8 ± 10.1-3.9 ± 9.13
Change in Non-Inflammatory Lesion Count from Baseline to Week 12-4.0 ± 22.0-4.9 ± 20.9
PrimaryNumber of Participants Demonstrating Efficacy Measured by Investigator Global Assessment Success

IGA (Investigator's Global Assessment) was used to assess the overall diseases severity on a scale of 0 to 4 (0=clear, 1=almost clear, 2=mild disease, 3=moderate disease, and 4=severe disease). IGA success was defined as a post-baseline score of 0 or 1 (yes=success, no=no success).

Time frame:
12 weeks
Reported as:
Count of participants · Participants
Number of Participants Demonstrating Efficacy Measured by Investigator Global Assessment Success
ParticipantsB244 ArmPlacebo Arm
Yes2512
No127137
Statistical analysis
  • B244 Arm vs Placebo Arm · ANCOVA · p = 0.034
SecondaryChange in Inflammatory and Non-inflammatory Lesion Count by Week

Lesion counting was performed using the digital photos taken by participants and stored inside the study mobile platform by trained personnel only. Every effort was made to have the counting and clinical evaluation done by the same evaluator for a given participant. Lesions under the jaw line or behind the hairline (including eyebrows) were not included in the counts. Papules, pustules, cysts and nodules were classified as inflammatory acne lesions, and open and closed comedones were classified as non-inflammatory lesions.

Time frame:
Baseline to weeks 2, 4, 8, 12 and 16
Reported as:
Mean · lesions
Change in Inflammatory and Non-inflammatory Lesion Count by Week
lesionsB244 ArmPlacebo Arm
Change in Inflammatory Lesion Count from Baseline to Week 2-1.5 ± 10.9-1.3 ± 9.94
Change in Inflammatory Lesion Count from Baseline to Week 4-0.8 ± 10.46-0.8 ± 9.49
Change in Inflammatory Lesion Count from Baseline to Week 8-3.3 ± 9.94-3.1 ± 8.75
Change in Inflammatory Lesion Count from Baseline to Week 12-4.8 ± 10.1-3.9 ± 9.13
Change in Inflammatory Lesion Count from Baseline to Week 16-3.2 ± 20.6-4.0 ± 11.4
Change in Non-Inflammatory Lesion Count from Baseline to Week 2-0.9 ± 17.1-2.1 ± 18.4
Change in Non-Inflammatory Lesion Count from Baseline to Week 4-1.5 ± 21.3-4.6 ± 19.1
Change in Non-Inflammatory Lesion Count from Baseline to Week 8-4.1 ± 20.4-5.8 ± 17.4
Change in Non-Inflammatory Lesion Count from Baseline to Week 12-4.0 ± 22.0-4.9 ± 20.9
Change in Non-Inflammatory Lesion Count from Baseline to Week 16-6.4 ± 23.2-6.1 ± 21.7
SecondaryNumber of Participants Demonstrating Efficacy Measured Investigator Global Assessment Score by Week

IGA (Investigator's Global Assessment) was used to assess the overall diseases severity on a scale of 0 to 4 (0=clear, 1=almost clear, 2=mild disease, 3=moderate disease, and 4=severe disease). IGA success was defined as a post-baseline score of 0 or 1 (yes=success, no=no success).

Time frame:
Baseline to weeks 2, 4, 8, 12 and 16
Reported as:
Count of participants · Participants
Number of Participants Demonstrating Efficacy Measured Investigator Global Assessment Score by Week
ParticipantsB244 ArmPlacebo Arm
Week 2 — Yes1213
Week 2 — No162157
Week 4 — Yes913
Week 4 — No159153
Week 8 — Yes1610
Week 8 — No144150
Week 12 — Yes2512
Week 12 — No127137
Week 16 — Yes1217
Week 16 — No140131
SecondaryChange in Patient Reported Quality of Life Score Using the Skindex-16 Questionnaire

The Skindex 16 questionnaire was assigned to subjects to examine the relationship between the subject's skin health and quality of life. Subjects scored 16 questions from 0 to 6 (0=never bothered, 6=always bothered). Total scores could range between 0 to 96, where a higher score is associated with a worse quality of life.

Time frame:
Baseline to weeks 2, 4, 8, 12 and 16
Reported as:
Mean · score on a scale
Change in Patient Reported Quality of Life Score Using the Skindex-16 Questionnaire
score on a scaleB244 ArmPlacebo Arm
Change from Baseline to Week 2-0.6 ± 1.05-1.6 ± 0.97
Change from Baseline to Week 4-0.7 ± 1.10-0.7 ± 1.12
Change from Baseline to Week 8-0.6 ± 1.23-0.7 ± 1.16
Change from Baseline to Week 12-0.7 ± 1.16-0.6 ± 1.17
Change from Baseline to Week 16-0.8 ± 1.16-0.7 ± 1.17
Other pre-specifiedTo Evaluate Facial Skin Microbiota

Evaluate if B244 administration on skin twice daily will affect the microbial content on collected skin swab samples.

Time frame:
baseline, week 4, week 8, week 12, and week 16

No measurements were reported for this outcome.

Adverse events

Collected over Baseline to Week 16.. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
B244 Arm0/181 (0%)3/181 (1.7%)39/181 (21.5%)
Placebo Arm0/179 (0%)2/179 (1.1%)42/179 (23.5%)
Most frequent serious events
Most frequent serious events
EventB244 ArmPlacebo Arm
PyrexiaGeneral disorders0/1811/179
GastroenteritisGastrointestinal disorders0/1811/179
NephrolithiasisRenal and urinary disorders1/1811/179
DepressionPsychiatric disorders1/1810/179
DyspnoeaRespiratory, thoracic and mediastinal disorders1/1810/179
Most frequent other events
Showing 10 of 56
Most frequent other events
EventB244 ArmPlacebo Arm
Viral upper respiratory tract infectionInfections and infestations7/1816/179
Dry skinSkin and subcutaneous tissue disorders2/1814/179
Pharyngitis streptococcalInfections and infestations0/1813/179
Upper respiratory tract infectionInfections and infestations3/1811/179
Psychiatric disordersInvestigations3/1810/179
DepressionInvestigations3/1810/179
Ear infectionInfections and infestations1/1812/179
PneumoniaInfections and infestations0/1812/179
SinusitisInfections and infestations2/1812/179
Urinary tract infectionInfections and infestations1/1812/179

Baseline characteristics

Efficacy analysis set: all subjects who received at least 1 application of IP

Age, Customized
Age, Customized(Participants)B244 ArmPlacebo ArmTotal
18 to <30 years126122248
30 to <65 years5557112
Sex: Female, Male
Sex: Female, Male(Participants)B244 ArmPlacebo ArmTotal
Female9592187
Male8687173
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)B244 ArmPlacebo ArmTotal
Hispanic or Latino393776
Not Hispanic or Latino137141278
Unknown or Not Reported516
Race (NIH/OMB)
Race (NIH/OMB)(Participants)B244 ArmPlacebo ArmTotal
American Indian or Alaska Native000
Asian272148
Native Hawaiian or Other Pacific Islander000
Black or African American19928
White107133240
More than one race000
Unknown or Not Reported281644
08

Study locations

1 site
  • Science37
    Culver City, California 90230, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Aug 2016 to primary completion in Jul 2017, 11 months.

Results were first posted in Sep 2022, 5 years 1 month after primary completion. A results delay was requested in Jul 2020.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 8, 2016
First posted
Jul 13, 2016
StartActual
Aug 2016
Primary completionActual
Jul 19, 2017
CompletionActual
Jul 19, 2017
Results delay requested
Jul 28, 2020
Results first posted
Sep 16, 2022
Last update
Sep 16, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 16, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02832063
Lead sponsor
AOBiome LLC
Responsible party
Sponsor
First posted
Jul 13, 2016
Start date
Aug 2016
Primary completion
Jul 19, 2017
Completion
Jul 19, 2017
Results posted
Sep 16, 2022
Last update
Sep 16, 2022

Study contacts

Noah Craft, MD
principal investigator · Science 37

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Nitrosomonas eutropha D23

Start the discussion